L&H finalizes Fonix purchase
L&H finalizes Fonix purchaseConsolidation continues in the speech-recognition sector. Lernout & Hauspie Speech Products has completed its acquisition of the Healthcare Solutions Group of fellow speech recognition firm Fonix, which has
L&H finalizes Fonix purchase
Consolidation continues in the speech-recognition sector. Lernout & Hauspie Speech Products has completed its acquisition of the Healthcare Solutions Group of fellow speech recognition firm Fonix, which has now exited the healthcare market. The deal combines Fonixs customer base, sales and marketing staff, and PowerScribe Radiology and Emergency Medicine speech-recognition products with L&H, which also features department-oriented medical-dictation products.
L&H paid $24 million for the Fonix business, plus future payments of up to $4 million over two years, based on performance. Fonixs Healthcare Solutions Group was formed last year following the companys acquisition of Articulate Systems and the PowerScribe business unit of the MRC Group (PNN 10/98).
Some 40 employees from Fonix are expected to become part of the L&H Healthcare Solutions Group, which will remain in Burlington, MA. Articulate Systems founder Ivan Mimica will assume the role of group vice president of Healthcare Solutions at L&H and will report to Anatoly Tikhman, president of L&Hs Speech and Language Applications division.
- Search again
- Homepage
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
